Molecular imaging of cellular immunotherapies in experimental and therapeutic settings Nourhan ShalabyVeronica Phyllis DuboisJohn Ronald Review Open access 17 October 2021 Pages: 1281 - 1294
Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma Kui CaoMingdong LiuJinhong Zhu Original Article 15 October 2021 Pages: 1295 - 1311
Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer Jun-Nan GuoDu ChenYan-Long Liu Original Article Open access 16 October 2021 Pages: 1313 - 1330
Cyclic sulfur compounds targeting macrophage polarization into M2/protumor phenotype and their anti-tumor effects Cheng PanYukio FujiwaraYoshihiro Komohara Original Article 16 October 2021 Pages: 1331 - 1343
First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis Mingfeng HeTaihao ZhengZhenzhou Yang Original Article 16 October 2021 Pages: 1345 - 1355
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer Miho TakahashiSatoshi WatanabeToshiaki Kikuchi Original Article 17 October 2021 Pages: 1357 - 1369
CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein–Barr virus genes Semjon SidorovLara FuxSimone Bürgler Original Article Open access 19 October 2021 Pages: 1371 - 1392
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study Jin-Ji YangCheng HuangYi-Long Wu Original Article 20 October 2021 Pages: 1393 - 1402
Immunogenic senescence sensitizes lung cancer to LUNX-targeting therapy Defeng JiaoXiaohu ZhengHaiming Wei Original Article Open access 21 October 2021 Pages: 1403 - 1417
Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial Toru KiguchiMasaki YamaguchiTomoki Naoe Original Article 22 October 2021 Pages: 1419 - 1430
Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer Meng QinJunzo HamanishiMasaki Mandai Original Article Open access 23 October 2021 Pages: 1431 - 1442
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study Kaili YangLu HanYunbo Zhao Original Article Open access 24 October 2021 Pages: 1443 - 1451
PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival Kelley G. NúñezTyler SandowPaul T. Thevenot Original Article Open access 24 October 2021 Pages: 1453 - 1465
Clinical determinants of long-term survival in metastatic uveal melanoma Elias A. T. KochAnne PetzoldMarkus V. Heppt Original Article Open access 28 October 2021 Pages: 1467 - 1477
Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing Divya RaviralaGuangsheng PeiXiaoliu Zhang Original Article 30 October 2021 Pages: 1479 - 1495
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer Mengmeng SunHan ZengZewei Wang Original Article 30 October 2021 Pages: 1497 - 1506
Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model Bo WangZhihua HeJian Huang Original Article 31 October 2021 Pages: 1507 - 1517
Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer Hui LiMiaofang WuJing Li Original Article 01 November 2021 Pages: 1519 - 1530
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit Emily NicklesBhushan DharmadhikariHerbert Schwarz Clinical Trial Report 18 October 2021 Pages: 1531 - 1543
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy V. ConteducaM. MedriI. Stanganelli Research Report 27 October 2021 Pages: 1545 - 1548